** Shares of drug developer Syndax Pharmaceuticals SNDX.O fall 5% to $14.86
** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago
** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago
** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer
** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025
** SNDX's shares have fallen 35% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。